Response to comment on "Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics". (2021)
Attributed to:
China kadoorie biobank - University of Oxford
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1126/scitranslmed.abf4530
PubMed Identifier: 34851696
Publication URI: http://europepmc.org/abstract/MED/34851696
Type: Journal Article/Review
Volume: 13
Parent Publication: Science translational medicine
Issue: 622
ISSN: 1946-6234